Asher Mullard
Impact in
- Oncology top 1%
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- Molecular Biology top 1%
- Protein Degradation and Inhibitors
- Ubiquitin and proteasome pathways
- RNA Interference and Gene Delivery
Papers in
-
- Biotechnology and Related Fields 47
- Co-authors
- Rujun Kang (3 shared papers)Roshni R. Singaraja (2 shared papers)Michael R. Hayden (2 shared papers)Pamela Arstikaitis (2 shared papers)Kun Huang (2 shared papers)Anat Yanai (2 shared papers)Alaa El-Husseini (2 shared papers)Brendan Haigh (1 shared paper)
- Journals
- Nature Reviews Drug Discovery (535 papers)Nature (26 papers)The Lancet (14 papers)Nature Reviews Molecular Cell Biology (14 papers)Nature Biotechnology (12 papers)
- Partner nations
- CanadaUnited StatesUnited Kingdom
In The Last Decade
Asher Mullard
585 papers receiving 10.2k citations
Asher Mullard's Hit Papers
Peers
Comparison fields: 5 of 188
- Oncology 2.1k
- Molecular Biology 4.9k
- Pharmaceutical Science 443
- Immunology 1.2k
- Computational Theory and Mathematics 910
Countries citing papers authored by Asher Mullard
This map shows the geographic impact of Asher Mullard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Asher Mullard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Asher Mullard more than expected).
Fields of papers citing papers by Asher Mullard
This network shows the impact of papers produced by Asher Mullard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Asher Mullard. The network helps show where Asher Mullard may publish in the future.
Co-authors
The 25 scholars most cited alongside Asher Mullard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 622 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | FDA approves 100th monoclonal antibody product Hit paper breakdown → | 2021 | 373 |
| 2 | Targeted protein degraders crowd into the clinic Hit paper breakdown → | 2021 | 285 |
| 3 | 2006 | 267 | |
| 4 | 2004 | 265 | |
| 5 | 2013 | 235 | |
| 6 | 2016 | 227 | |
| 7 | 2012 | 208 | |
| 8 | 2020 | 177 | |
| 9 | 2019 | 165 | |
| 10 | 2017 | 159 | |
| 11 | 2014 | 152 | |
| 12 | 2021 | 147 | |
| 13 | 2012 | 133 | |
| 14 | 2019 | 124 | |
| 15 | 2020 | 120 | |
| 16 | 2018 | 118 | |
| 17 | 2013 | 115 | |
| 18 | 2016 | 108 | |
| 19 | 2016 | 107 | |
| 20 | 2017 | 105 |
About Asher Mullard
Asher Mullard is a scholar working on Molecular Biology, Public Health, Environmental and Occupational Health, Reproductive Medicine, Economics and Econometrics and Oncology, having authored 622 papers that have together received 10.6k indexed citations. Recurring topics across this work include Science, Research, and Medicine (76 papers), Biotechnology and Related Fields (47 papers), Biomedical Ethics and Regulation (44 papers), Pharmaceutical Economics and Policy (44 papers), Health Systems, Economic Evaluations, Quality of Life (35 papers), Monoclonal and Polyclonal Antibodies Research (32 papers), Biosimilars and Bioanalytical Methods (29 papers) and CAR-T cell therapy research (28 papers). The work is most often cited by research in Oncology (2.1k citations), Molecular Biology (4.9k citations), Pharmaceutical Science (443 citations), Immunology (1.2k citations) and Computational Theory and Mathematics (910 citations). Asher Mullard has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Rujun Kang, Roshni R. Singaraja, Michael R. Hayden, Pamela Arstikaitis, Kun Huang, Anat Yanai, Alaa El-Husseini, Brendan Haigh, Martina Metzler and Claire‐Anne Gutekunst. Their work appears in journals such as Nature Reviews Drug Discovery, Nature, The Lancet, Nature Reviews Molecular Cell Biology and Nature Biotechnology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.